Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Testosterone | 53 | 2021 | 2491 | 3.370 |
Why?
|
Muscle Strength | 21 | 2019 | 640 | 1.760 |
Why?
|
Body Composition | 30 | 2018 | 2462 | 1.680 |
Why?
|
Muscle, Skeletal | 40 | 2019 | 4978 | 1.680 |
Why?
|
Physical Fitness | 8 | 2020 | 744 | 1.510 |
Why?
|
Exercise Test | 18 | 2020 | 2186 | 1.240 |
Why?
|
Hormone Replacement Therapy | 9 | 2018 | 757 | 1.210 |
Why?
|
Mobility Limitation | 9 | 2020 | 409 | 1.200 |
Why?
|
Physical Endurance | 13 | 2015 | 369 | 1.160 |
Why?
|
Oxygen Consumption | 14 | 2018 | 1880 | 1.120 |
Why?
|
Androgens | 16 | 2020 | 1281 | 1.110 |
Why?
|
Muscle Fatigue | 4 | 2008 | 96 | 0.750 |
Why?
|
Exercise Therapy | 5 | 2009 | 939 | 0.680 |
Why?
|
Aging | 14 | 2020 | 8744 | 0.590 |
Why?
|
Hypogonadism | 6 | 2018 | 805 | 0.580 |
Why?
|
Renal Dialysis | 7 | 2015 | 1791 | 0.560 |
Why?
|
Geriatric Assessment | 2 | 2020 | 1422 | 0.520 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 560 | 0.490 |
Why?
|
Double-Blind Method | 29 | 2021 | 12465 | 0.450 |
Why?
|
Accidental Falls | 5 | 2020 | 1080 | 0.390 |
Why?
|
Cross Infection | 1 | 2020 | 1426 | 0.380 |
Why?
|
Dietary Proteins | 4 | 2021 | 960 | 0.370 |
Why?
|
Resistance Training | 4 | 2015 | 198 | 0.370 |
Why?
|
Anabolic Agents | 4 | 2011 | 256 | 0.350 |
Why?
|
Renal Insufficiency | 2 | 2007 | 812 | 0.350 |
Why?
|
Motor Activity | 5 | 2014 | 2711 | 0.350 |
Why?
|
Occupational Health | 2 | 2014 | 812 | 0.350 |
Why?
|
HIV Wasting Syndrome | 3 | 2005 | 99 | 0.340 |
Why?
|
Exercise | 14 | 2019 | 5955 | 0.320 |
Why?
|
Dentate Gyrus | 2 | 2020 | 165 | 0.320 |
Why?
|
Growth Substances | 2 | 2006 | 759 | 0.290 |
Why?
|
Somatomedins | 1 | 2007 | 179 | 0.280 |
Why?
|
Leuprolide | 2 | 2008 | 313 | 0.280 |
Why?
|
Sarcopenia | 3 | 2019 | 378 | 0.270 |
Why?
|
Doping in Sports | 2 | 2009 | 62 | 0.260 |
Why?
|
Quadriceps Muscle | 1 | 2007 | 157 | 0.260 |
Why?
|
Death, Sudden, Cardiac | 1 | 2014 | 1567 | 0.250 |
Why?
|
Male | 92 | 2021 | 364719 | 0.250 |
Why?
|
Nandrolone | 1 | 2005 | 16 | 0.250 |
Why?
|
Weight Lifting | 4 | 2013 | 130 | 0.240 |
Why?
|
Myostatin | 5 | 2011 | 129 | 0.240 |
Why?
|
Leg | 3 | 2008 | 1088 | 0.240 |
Why?
|
Atherosclerosis | 2 | 2018 | 3433 | 0.240 |
Why?
|
Aged | 52 | 2021 | 171504 | 0.240 |
Why?
|
Androgen Antagonists | 2 | 2012 | 1412 | 0.240 |
Why?
|
Receptors, Androgen | 5 | 2016 | 1089 | 0.230 |
Why?
|
Kidney Failure, Chronic | 5 | 2011 | 2496 | 0.230 |
Why?
|
Human Growth Hormone | 2 | 2009 | 651 | 0.230 |
Why?
|
Lung Diseases, Obstructive | 3 | 2010 | 311 | 0.230 |
Why?
|
Transforming Growth Factor beta | 4 | 2007 | 1996 | 0.220 |
Why?
|
Sexual Behavior | 6 | 2016 | 2197 | 0.220 |
Why?
|
Administration, Cutaneous | 5 | 2020 | 716 | 0.220 |
Why?
|
Physical Exertion | 7 | 2014 | 668 | 0.220 |
Why?
|
Muscle Contraction | 4 | 2008 | 1209 | 0.210 |
Why?
|
5-alpha Reductase Inhibitors | 2 | 2016 | 112 | 0.210 |
Why?
|
CA3 Region, Hippocampal | 2 | 2020 | 54 | 0.210 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 5 | 2014 | 3252 | 0.210 |
Why?
|
Walking | 5 | 2018 | 1201 | 0.210 |
Why?
|
Placebos | 6 | 2018 | 1667 | 0.200 |
Why?
|
Gels | 3 | 2020 | 423 | 0.200 |
Why?
|
Hysterectomy | 2 | 2019 | 863 | 0.190 |
Why?
|
Health Promotion | 1 | 2014 | 2210 | 0.190 |
Why?
|
Gonadal Steroid Hormones | 4 | 2014 | 707 | 0.190 |
Why?
|
Fatigue | 5 | 2018 | 1557 | 0.190 |
Why?
|
Absorptiometry, Photon | 8 | 2021 | 1758 | 0.180 |
Why?
|
Humans | 103 | 2021 | 768166 | 0.180 |
Why?
|
Lung | 2 | 2018 | 10099 | 0.180 |
Why?
|
Activities of Daily Living | 2 | 2021 | 2430 | 0.170 |
Why?
|
Exercise Tolerance | 4 | 2009 | 846 | 0.170 |
Why?
|
Muscle Fibers, Skeletal | 3 | 2011 | 553 | 0.170 |
Why?
|
3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2017 | 74 | 0.160 |
Why?
|
Lactates | 6 | 2007 | 401 | 0.160 |
Why?
|
Middle Aged | 49 | 2020 | 223492 | 0.160 |
Why?
|
RNA, Messenger | 6 | 2011 | 12800 | 0.160 |
Why?
|
Nurse's Role | 1 | 2020 | 188 | 0.160 |
Why?
|
Discrimination Learning | 1 | 2020 | 278 | 0.160 |
Why?
|
Body Mass Index | 8 | 2017 | 13053 | 0.160 |
Why?
|
Sexuality | 2 | 2014 | 179 | 0.150 |
Why?
|
Insulin-Like Growth Factor I | 6 | 2007 | 1942 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2019 | 10760 | 0.150 |
Why?
|
Fitness Centers | 2 | 2014 | 13 | 0.150 |
Why?
|
Weight Loss | 6 | 2009 | 2721 | 0.140 |
Why?
|
Geriatric Nursing | 1 | 2017 | 39 | 0.140 |
Why?
|
Agrin | 1 | 2017 | 75 | 0.140 |
Why?
|
Lung Volume Measurements | 1 | 2018 | 381 | 0.140 |
Why?
|
Asymptomatic Infections | 1 | 2018 | 136 | 0.140 |
Why?
|
Patient Care Management | 1 | 2020 | 303 | 0.140 |
Why?
|
Blood Glucose | 5 | 2021 | 6430 | 0.140 |
Why?
|
Health Status | 5 | 2018 | 4091 | 0.140 |
Why?
|
Risk Assessment | 7 | 2020 | 24315 | 0.140 |
Why?
|
Task Performance and Analysis | 1 | 2020 | 771 | 0.140 |
Why?
|
Adult | 48 | 2019 | 223646 | 0.130 |
Why?
|
Intra-Abdominal Fat | 1 | 2021 | 625 | 0.130 |
Why?
|
Body Weight | 7 | 2014 | 4627 | 0.130 |
Why?
|
Finasteride | 1 | 2016 | 86 | 0.130 |
Why?
|
Independent Living | 4 | 2020 | 584 | 0.130 |
Why?
|
Receptor, IGF Type 1 | 3 | 2006 | 384 | 0.120 |
Why?
|
Aged, 80 and over | 16 | 2020 | 59629 | 0.120 |
Why?
|
Wounds and Injuries | 2 | 2018 | 2517 | 0.120 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2016 | 193 | 0.120 |
Why?
|
Muscle Weakness | 2 | 2012 | 412 | 0.120 |
Why?
|
Pulmonary Gas Exchange | 4 | 2008 | 389 | 0.110 |
Why?
|
Body Temperature | 4 | 2013 | 780 | 0.110 |
Why?
|
Skinfold Thickness | 1 | 2014 | 164 | 0.110 |
Why?
|
Patients | 1 | 2020 | 908 | 0.110 |
Why?
|
Luteinizing Hormone | 4 | 2004 | 822 | 0.110 |
Why?
|
HIV Infections | 7 | 2019 | 17569 | 0.100 |
Why?
|
Hypopituitarism | 1 | 2014 | 253 | 0.100 |
Why?
|
Amphetamine-Related Disorders | 1 | 2013 | 80 | 0.100 |
Why?
|
Azasteroids | 1 | 2012 | 37 | 0.100 |
Why?
|
Protective Devices | 1 | 2012 | 72 | 0.100 |
Why?
|
Forced Expiratory Volume | 2 | 2014 | 1831 | 0.100 |
Why?
|
Alopecia | 1 | 2016 | 416 | 0.100 |
Why?
|
Capillaries | 1 | 2015 | 755 | 0.100 |
Why?
|
Residential Treatment | 1 | 2013 | 112 | 0.100 |
Why?
|
Oxygen Inhalation Therapy | 2 | 2010 | 418 | 0.100 |
Why?
|
Treatment Outcome | 12 | 2020 | 65371 | 0.100 |
Why?
|
Body Temperature Regulation | 1 | 2013 | 292 | 0.090 |
Why?
|
Female | 40 | 2020 | 397192 | 0.090 |
Why?
|
Energy Intake | 3 | 2017 | 2146 | 0.090 |
Why?
|
Spleen | 1 | 2017 | 2295 | 0.090 |
Why?
|
Psychomotor Performance | 1 | 2019 | 1892 | 0.090 |
Why?
|
Vital Capacity | 1 | 2014 | 996 | 0.090 |
Why?
|
Fires | 1 | 2012 | 170 | 0.090 |
Why?
|
Nitric Oxide Synthase Type I | 1 | 2011 | 175 | 0.090 |
Why?
|
Methamphetamine | 1 | 2013 | 167 | 0.090 |
Why?
|
Gonadotropin-Releasing Hormone | 3 | 2008 | 1149 | 0.090 |
Why?
|
Hand Strength | 1 | 2014 | 466 | 0.090 |
Why?
|
Wasting Syndrome | 2 | 2009 | 96 | 0.090 |
Why?
|
Reproducibility of Results | 6 | 2020 | 20227 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2020 | 10399 | 0.090 |
Why?
|
Muscle Proteins | 4 | 2012 | 1165 | 0.090 |
Why?
|
Anaerobic Threshold | 2 | 2008 | 52 | 0.080 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2011 | 514 | 0.080 |
Why?
|
Oxygen | 3 | 2010 | 4270 | 0.080 |
Why?
|
Memory | 1 | 2019 | 2208 | 0.080 |
Why?
|
Clinical Trials as Topic | 4 | 2018 | 8054 | 0.080 |
Why?
|
Habits | 1 | 2010 | 148 | 0.080 |
Why?
|
Community Health Services | 1 | 2014 | 659 | 0.080 |
Why?
|
Cholestenone 5 alpha-Reductase | 1 | 2009 | 21 | 0.080 |
Why?
|
Prostatic Neoplasms | 1 | 2012 | 11101 | 0.080 |
Why?
|
Muscle Fibers, Slow-Twitch | 2 | 2006 | 52 | 0.080 |
Why?
|
Muscle Fibers, Fast-Twitch | 2 | 2006 | 71 | 0.080 |
Why?
|
Lactic Acid | 6 | 2008 | 1140 | 0.080 |
Why?
|
Insulin Resistance | 2 | 2018 | 3986 | 0.080 |
Why?
|
Breath Tests | 1 | 2010 | 300 | 0.080 |
Why?
|
Patient Participation | 1 | 2017 | 1447 | 0.080 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2011 | 706 | 0.080 |
Why?
|
Research Design | 3 | 2017 | 6211 | 0.070 |
Why?
|
Quality of Life | 7 | 2018 | 13490 | 0.070 |
Why?
|
Affect | 4 | 2018 | 1495 | 0.070 |
Why?
|
Reproduction | 1 | 2012 | 646 | 0.070 |
Why?
|
Nerve Net | 1 | 2019 | 2352 | 0.070 |
Why?
|
Growth Hormone | 1 | 2009 | 573 | 0.070 |
Why?
|
Insulin-Like Growth Factor II | 2 | 2006 | 271 | 0.070 |
Why?
|
Organ Size | 4 | 2019 | 2267 | 0.070 |
Why?
|
Hippocampus | 1 | 2019 | 3785 | 0.070 |
Why?
|
HIV | 2 | 2018 | 1597 | 0.070 |
Why?
|
Ergometry | 2 | 2004 | 17 | 0.070 |
Why?
|
Sex Hormone-Binding Globulin | 3 | 2004 | 553 | 0.070 |
Why?
|
Peptide Fragments | 2 | 2017 | 5151 | 0.070 |
Why?
|
Glycogen | 1 | 2006 | 252 | 0.060 |
Why?
|
Internationality | 1 | 2011 | 1008 | 0.060 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2006 | 208 | 0.060 |
Why?
|
Mitochondria, Muscle | 1 | 2006 | 172 | 0.060 |
Why?
|
Libido | 2 | 2016 | 124 | 0.060 |
Why?
|
Cholesterol | 1 | 2014 | 2914 | 0.060 |
Why?
|
Androstenedione | 1 | 2004 | 132 | 0.060 |
Why?
|
Substance-Related Disorders | 1 | 2001 | 4423 | 0.060 |
Why?
|
Catheterization | 1 | 2010 | 1430 | 0.060 |
Why?
|
Heart Rate | 2 | 2013 | 4214 | 0.060 |
Why?
|
Cognition | 2 | 2016 | 7073 | 0.060 |
Why?
|
Biopsy | 3 | 2018 | 6793 | 0.060 |
Why?
|
Time Factors | 4 | 2018 | 40218 | 0.060 |
Why?
|
Anti-Retroviral Agents | 1 | 2013 | 1789 | 0.060 |
Why?
|
Disease Progression | 2 | 2018 | 13671 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2013 | 3228 | 0.050 |
Why?
|
Mental Health | 1 | 2018 | 3275 | 0.050 |
Why?
|
Age Factors | 4 | 2008 | 18412 | 0.050 |
Why?
|
Adipose Tissue | 3 | 2005 | 3329 | 0.050 |
Why?
|
Appetite | 1 | 2005 | 247 | 0.050 |
Why?
|
Oxymetholone | 1 | 2002 | 8 | 0.050 |
Why?
|
Muscles | 2 | 1998 | 1582 | 0.050 |
Why?
|
Reference Values | 5 | 2016 | 4938 | 0.050 |
Why?
|
Young Adult | 11 | 2019 | 60066 | 0.050 |
Why?
|
Chronic Disease | 2 | 2009 | 9384 | 0.050 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2016 | 364 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2013 | 4352 | 0.050 |
Why?
|
Adiposity | 1 | 2012 | 1895 | 0.050 |
Why?
|
Intubation, Intratracheal | 1 | 2010 | 1359 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7064 | 0.050 |
Why?
|
Liver | 1 | 2017 | 7577 | 0.050 |
Why?
|
Risk Factors | 5 | 2020 | 74944 | 0.050 |
Why?
|
Consensus | 1 | 2011 | 3212 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 9 | 2020 | 36743 | 0.050 |
Why?
|
Body Water | 1 | 2001 | 340 | 0.040 |
Why?
|
Pigmentation Disorders | 1 | 2001 | 105 | 0.040 |
Why?
|
Metabolic Diseases | 1 | 2006 | 684 | 0.040 |
Why?
|
Nutritional Physiological Phenomena | 1 | 2001 | 360 | 0.040 |
Why?
|
Work | 1 | 1980 | 195 | 0.040 |
Why?
|
Muscle Development | 1 | 2001 | 258 | 0.040 |
Why?
|
Respiratory Function Tests | 1 | 2004 | 1695 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4580 | 0.040 |
Why?
|
Glucocorticoids | 1 | 2009 | 2167 | 0.040 |
Why?
|
Depressive Disorder, Major | 1 | 2016 | 4818 | 0.040 |
Why?
|
Pelvic Floor | 1 | 2019 | 138 | 0.040 |
Why?
|
Menopause, Premature | 1 | 2019 | 124 | 0.040 |
Why?
|
Inflammation | 1 | 2018 | 10873 | 0.040 |
Why?
|
Physical Education and Training | 2 | 2009 | 102 | 0.040 |
Why?
|
Blood Pressure | 1 | 2014 | 8543 | 0.040 |
Why?
|
Rejuvenation | 1 | 2019 | 109 | 0.040 |
Why?
|
Cross-Sectional Studies | 4 | 2014 | 26379 | 0.040 |
Why?
|
Anger | 2 | 1996 | 405 | 0.030 |
Why?
|
Sex Factors | 4 | 2020 | 10632 | 0.030 |
Why?
|
Hair | 1 | 2001 | 508 | 0.030 |
Why?
|
Carbon Dioxide | 2 | 2002 | 1148 | 0.030 |
Why?
|
Patient Compliance | 3 | 2014 | 2697 | 0.030 |
Why?
|
Adolescent | 10 | 2019 | 89169 | 0.030 |
Why?
|
Models, Biological | 3 | 2008 | 9495 | 0.030 |
Why?
|
Central Nervous System Diseases | 1 | 2001 | 520 | 0.030 |
Why?
|
Receptor, IGF Type 2 | 2 | 2006 | 35 | 0.030 |
Why?
|
Lipids | 4 | 2012 | 3343 | 0.030 |
Why?
|
Fatty Acids | 1 | 2003 | 1812 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 3814 | 0.030 |
Why?
|
Viremia | 1 | 2018 | 726 | 0.030 |
Why?
|
Organ Specificity | 2 | 2012 | 1968 | 0.030 |
Why?
|
Forecasting | 2 | 2019 | 2945 | 0.030 |
Why?
|
Risk Management | 1 | 2017 | 558 | 0.030 |
Why?
|
Prostate | 2 | 2012 | 1765 | 0.030 |
Why?
|
Pelvis | 1 | 2018 | 736 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2014 | 15948 | 0.030 |
Why?
|
Calorimetry, Indirect | 1 | 2013 | 176 | 0.030 |
Why?
|
Regression Analysis | 3 | 2004 | 6340 | 0.030 |
Why?
|
Sebum | 1 | 2012 | 17 | 0.020 |
Why?
|
Ovariectomy | 1 | 2014 | 613 | 0.020 |
Why?
|
Erectile Dysfunction | 1 | 2014 | 437 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2012 | 6229 | 0.020 |
Why?
|
Respiration | 3 | 2002 | 1665 | 0.020 |
Why?
|
Hematocrit | 1 | 2012 | 623 | 0.020 |
Why?
|
Dyspnea | 2 | 2014 | 1352 | 0.020 |
Why?
|
Obesity Hypoventilation Syndrome | 1 | 2010 | 17 | 0.020 |
Why?
|
Thigh | 2 | 2003 | 238 | 0.020 |
Why?
|
Gene Expression | 2 | 2016 | 7598 | 0.020 |
Why?
|
Cold Temperature | 1 | 2013 | 791 | 0.020 |
Why?
|
Gait | 1 | 2014 | 823 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2015 | 2227 | 0.020 |
Why?
|
Kinetics | 3 | 2004 | 6329 | 0.020 |
Why?
|
Life Style | 3 | 2006 | 3932 | 0.020 |
Why?
|
Depression | 2 | 2020 | 8230 | 0.020 |
Why?
|
Arousal | 1 | 2014 | 1180 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 4 | 1 | 2007 | 24 | 0.020 |
Why?
|
Insulin | 2 | 2018 | 6607 | 0.020 |
Why?
|
Differential Threshold | 1 | 2007 | 80 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2596 | 0.020 |
Why?
|
SKP Cullin F-Box Protein Ligases | 1 | 2007 | 174 | 0.020 |
Why?
|
Health Education | 1 | 2013 | 1059 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 2016 | 2463 | 0.020 |
Why?
|
Carbohydrate Metabolism | 1 | 2007 | 262 | 0.020 |
Why?
|
Myosin Heavy Chains | 1 | 2007 | 404 | 0.020 |
Why?
|
Anxiety | 1 | 2020 | 4672 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8741 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 2010 | 772 | 0.020 |
Why?
|
Postmenopause | 1 | 2014 | 2518 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2018 | 3390 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2010 | 15662 | 0.010 |
Why?
|
Central Nervous System Stimulants | 1 | 2013 | 1168 | 0.010 |
Why?
|
California | 1 | 2008 | 1438 | 0.010 |
Why?
|
Administration, Oral | 1 | 2012 | 4030 | 0.010 |
Why?
|
Coronary Vessels | 1 | 2015 | 3124 | 0.010 |
Why?
|
Primary Health Care | 1 | 2020 | 4746 | 0.010 |
Why?
|
Electrocardiography | 1 | 2017 | 6412 | 0.010 |
Why?
|
Energy Metabolism | 1 | 1995 | 2907 | 0.010 |
Why?
|
Behavior | 2 | 1996 | 542 | 0.010 |
Why?
|
Needs Assessment | 1 | 2009 | 1141 | 0.010 |
Why?
|
Health Status Indicators | 1 | 2008 | 969 | 0.010 |
Why?
|
Sports | 1 | 2009 | 703 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2016 | 7140 | 0.010 |
Why?
|
Respiratory Dead Space | 1 | 2002 | 31 | 0.010 |
Why?
|
Menstruation | 1 | 2004 | 310 | 0.010 |
Why?
|
3T3 Cells | 1 | 2004 | 1084 | 0.010 |
Why?
|
Hypertension | 2 | 2015 | 8616 | 0.010 |
Why?
|
Linear Models | 2 | 2007 | 5884 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2007 | 1715 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2008 | 2862 | 0.010 |
Why?
|
Muscular Atrophy | 1 | 2005 | 335 | 0.010 |
Why?
|
Animals | 3 | 2011 | 169246 | 0.010 |
Why?
|
Calcium | 1 | 2015 | 5792 | 0.010 |
Why?
|
Anatomy, Cross-Sectional | 1 | 2002 | 139 | 0.010 |
Why?
|
Equipment Design | 1 | 2010 | 3522 | 0.010 |
Why?
|
Osmolar Concentration | 1 | 2003 | 657 | 0.010 |
Why?
|
Incidence | 1 | 2020 | 21538 | 0.010 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2002 | 192 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2013 | 5315 | 0.010 |
Why?
|
Gene Expression Regulation | 2 | 2011 | 11928 | 0.010 |
Why?
|
Health Behavior | 1 | 2013 | 2650 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2017 | 3837 | 0.010 |
Why?
|
Drug Design | 1 | 2006 | 1046 | 0.010 |
Why?
|
Boston | 1 | 2013 | 9374 | 0.010 |
Why?
|
Obesity | 2 | 2015 | 13090 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10266 | 0.010 |
Why?
|
Lower Extremity | 1 | 2008 | 1216 | 0.010 |
Why?
|
Methods | 1 | 1980 | 1066 | 0.010 |
Why?
|
Hypertrophy | 1 | 2002 | 562 | 0.010 |
Why?
|
Tidal Volume | 1 | 2002 | 518 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10840 | 0.010 |
Why?
|
Research | 1 | 2008 | 1979 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6526 | 0.010 |
Why?
|
Nutrition Assessment | 1 | 2002 | 740 | 0.010 |
Why?
|
Actins | 1 | 2006 | 2064 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10590 | 0.010 |
Why?
|
Hormones | 1 | 2003 | 866 | 0.010 |
Why?
|
Reference Standards | 1 | 2002 | 1014 | 0.010 |
Why?
|
Melanins | 1 | 2001 | 292 | 0.010 |
Why?
|
Sickness Impact Profile | 1 | 2000 | 299 | 0.010 |
Why?
|
Dihydrotestosterone | 1 | 1998 | 195 | 0.010 |
Why?
|
Air | 1 | 1998 | 187 | 0.010 |
Why?
|
Ligands | 1 | 2004 | 3284 | 0.010 |
Why?
|
Melanocytes | 1 | 2001 | 509 | 0.010 |
Why?
|
Gonadotropins, Pituitary | 1 | 1996 | 70 | 0.010 |
Why?
|
Keratinocytes | 1 | 2001 | 876 | 0.010 |
Why?
|
Follicle Stimulating Hormone | 1 | 1998 | 727 | 0.010 |
Why?
|
Fasting | 1 | 2002 | 1610 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 41754 | 0.010 |
Why?
|
Logistic Models | 1 | 2010 | 13290 | 0.010 |
Why?
|
Data Collection | 1 | 2004 | 3327 | 0.010 |
Why?
|
Injections, Intramuscular | 1 | 1996 | 556 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2003 | 4860 | 0.010 |
Why?
|
Norepinephrine | 2 | 1987 | 898 | 0.010 |
Why?
|
Syndrome | 1 | 2001 | 3272 | 0.010 |
Why?
|
Single-Blind Method | 1 | 1998 | 1587 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2004 | 2176 | 0.010 |
Why?
|
United States | 2 | 2014 | 73039 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2011 | 22291 | 0.010 |
Why?
|
Epinephrine | 2 | 1987 | 794 | 0.010 |
Why?
|
Prospective Studies | 1 | 2018 | 54926 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2003 | 4249 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2002 | 2650 | 0.010 |
Why?
|
Treatment Failure | 1 | 1998 | 2661 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 1998 | 2107 | 0.010 |
Why?
|
Models, Statistical | 1 | 2006 | 5107 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2009 | 39348 | 0.000 |
Why?
|
Skin | 1 | 2001 | 4503 | 0.000 |
Why?
|
Cell Differentiation | 1 | 2004 | 11669 | 0.000 |
Why?
|
Emotions | 1 | 1998 | 2767 | 0.000 |
Why?
|
Mice | 1 | 2004 | 82029 | 0.000 |
Why?
|